Divis Laboratories Ltd

Divis Laboratories Ltd Share Price Today: Live Updates & Key Insights

Get insights on Divis Laboratories Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Divis Laboratories Ltd Share Price Chart

Divis Laboratories Ltd Fundamentals

Traded Volume: 50,608

Market Cap(Cr): 1,71,400

Avg Traded Price 6498.90

1 Year return 6.32%

Upper Circuit 6,542

Lower Circuit 6,451

P/E TTM 69.00

P/B Ratio 94.00

Traded Value(Cr) 3267.51

EPS TTM 93.608

Book value 93.608

Dividend Yield 1Y 0.46%

Divis Laboratories Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Divis Laboratories Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Divis Laboratories Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W +0.04%

1M -0.52%

3M +4.30%

1Y +6.32%

YTD +7.20%

Divis Laboratories Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Divis Laboratories Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 1.27L

Day Before Yesterday 1.80L

1W Avg 1.89L

1M Avg 3.73L

3M Avg 4.15L

Divis Laboratories Ltd Technical Details

Divis Laboratories Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 6438

Support 2 6365

Support 3 6319

Pivot Point : 6484

Resistance 1 6556

Resistance 2 6602

Resistance 3 6675

Divis Laboratories Ltd Corporate Actions

Divis Laboratories Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Divis Laboratories Ltd’s capital allocation strategies.

All

Ex-Date 25-Jul-2025 Type D Description 30.00/share@1500.00% Record Date 25-Jul-2025 Ratio 1500.00

Ex-Date 02-Aug-2024 Type D Description 30.00/share@1500.00% Record Date 02-Aug-2024 Ratio 1500.00

Ex-Date 11-Aug-2023 Type D Description 30.00/share@1500.00% Record Date 11-Aug-2023 Ratio 1500.00

Ex-Date 11-Aug-2022 Type D Description 30.00/share@1500.00% Record Date 12-Aug-2022 Ratio 1500.00

Ex-Date 17-Aug-2021 Type D Description 20.00/share@1000.00% Record Date - Ratio 1000.00

Ex-Date 25-Feb-2020 Type D Description 16.00/share@800.00% Record Date 26-Feb-2020 Ratio 800.00

Ex-Date 14-Aug-2019 Type D Description 16.00/share@800.00% Record Date - Ratio 800.00

Ex-Date 31-Aug-2018 Type D Description 10.00/share@500.00% Record Date - Ratio 500.00

Ex-Date 15-Sep-2017 Type D Description 10.00/share@500.00% Record Date - Ratio 500.00

Ex-Date 17-Mar-2016 Type D Description 10.00/share@500.00% Record Date 18-Mar-2016 Ratio 500.00

Ex-Date 23-Sep-2015 Type B Description share@1:1 Record Date 26-Sep-2015 Ratio 1:1

Ex-Date 06-Aug-2015 Type D Description 20.00/share@1000.00% Record Date - Ratio 1000.00

Ex-Date 31-Jul-2014 Type D Description 20.00/share@1000.00% Record Date - Ratio 1000.00

Ex-Date 25-Jul-2013 Type D Description 15.00/share@750.00% Record Date - Ratio 750.00

Ex-Date 26-Jul-2012 Type D Description 13.00/share@650.00% Record Date - Ratio 650.00

Ex-Date 16-Jun-2011 Type D Description 10.00/share@500.00% Record Date - Ratio 500.00

Ex-Date 02-Jul-2010 Type D Description 6.00/share@300.00% Record Date - Ratio 300.00

Ex-Date 30-Jul-2009 Type B Description share@1:1 Record Date 01-Aug-2009 Ratio 1:1

Ex-Date 15-Jun-2009 Type D Description 6.00/share@300.00% Record Date - Ratio 300.00

Ex-Date 26-Jun-2008 Type D Description 4.00/share@200.00% Record Date - Ratio 200.00

Ex-Date 03-Aug-2007 Type S Description share@1:5.00 Record Date 10-Aug-2007 Ratio 1:5.00

Ex-Date 23-Mar-2007 Type D Description 2.00/share@100.00% Record Date 26-Mar-2007 Ratio 100.00

Dividends

Announcement Date 25-Jul-2025 Ex Dividend Date 25-Jul-2025 Dividend(%) 1500

Announcement Date 02-Aug-2024 Ex Dividend Date 02-Aug-2024 Dividend(%) 1500

Announcement Date 11-Aug-2023 Ex Dividend Date 11-Aug-2023 Dividend(%) 1500

Announcement Date 11-Aug-2022 Ex Dividend Date 11-Aug-2022 Dividend(%) 1500

Announcement Date 17-Aug-2021 Ex Dividend Date 17-Aug-2021 Dividend(%) 1000

Announcement Date 25-Feb-2020 Ex Dividend Date 25-Feb-2020 Dividend(%) 800

Announcement Date 14-Aug-2019 Ex Dividend Date 14-Aug-2019 Dividend(%) 800

Announcement Date 31-Aug-2018 Ex Dividend Date 31-Aug-2018 Dividend(%) 500

Announcement Date 15-Sep-2017 Ex Dividend Date 15-Sep-2017 Dividend(%) 500

Announcement Date 17-Mar-2016 Ex Dividend Date 17-Mar-2016 Dividend(%) 500

Announcement Date 06-Aug-2015 Ex Dividend Date 06-Aug-2015 Dividend(%) 1000

Announcement Date 31-Jul-2014 Ex Dividend Date 31-Jul-2014 Dividend(%) 1000

Announcement Date 25-Jul-2013 Ex Dividend Date 25-Jul-2013 Dividend(%) 750

Announcement Date 26-Jul-2012 Ex Dividend Date 26-Jul-2012 Dividend(%) 650

Announcement Date 16-Jun-2011 Ex Dividend Date 16-Jun-2011 Dividend(%) 500

Announcement Date 02-Jul-2010 Ex Dividend Date 02-Jul-2010 Dividend(%) 300

Announcement Date 15-Jun-2009 Ex Dividend Date 15-Jun-2009 Dividend(%) 300

Announcement Date 26-Jun-2008 Ex Dividend Date 26-Jun-2008 Dividend(%) 200

Announcement Date 23-Mar-2007 Ex Dividend Date 23-Mar-2007 Dividend(%) 100

Bonus

Record Date 26-Sep-2015 Ex-Bonus Date 23-Sep-2015 Ratio 1:1

Record Date 01-Aug-2009 Ex-Bonus Date 30-Jul-2009 Ratio 1:1

Splits

Record Date 10-Aug-2007 Split Date 03-Aug-2007 Face Value (Before/After) 10.00/2.00

Others

Rights No Rights has been declared by DIVISLAB

Divis Laboratories Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Divis Laboratories Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Divis Laboratories Ltd's relative performance and valuation against major competitors.

Stock Name Sun Pharmaceutical Industries Ltd ₹1809.80 (+0.27%) M. Cap (Cr) 4342.32 1 Yr Return (%) +2.74% P/E (TTM) 41.60 PB Ratio 6.02

Stock Name Divis Laboratories Ltd ₹6456.50 (-0.82%) M. Cap (Cr) 1714.00 1 Yr Return (%) +6.32% P/E (TTM) 69.00 PB Ratio 11.45

Stock Name Torrent Pharmaceuticals Ltd ₹3729.60 (-0.70%) M. Cap (Cr) 1262.21 1 Yr Return (%) +15.63% P/E (TTM) 58.96 PB Ratio 16.81

Stock Name Cipla Ltd ₹1525.10 (+0.09%) M. Cap (Cr) 1231.93 1 Yr Return (%) +2.17% P/E (TTM) 22.64 PB Ratio 3.95

Stock Name Dr Reddys Laboratories Ltd ₹1244.60 (-0.27%) M. Cap (Cr) 1038.77 1 Yr Return (%) +2.97% P/E (TTM) 17.99 PB Ratio 3.09

Stock Name Zydus Lifesciences Ltd ₹934.10 (-0.69%) M. Cap (Cr) 939.92 1 Yr Return (%) -1.98% P/E (TTM) 19.09 PB Ratio 3.92

Stock Name Lupin Ltd ₹2077.00 (+0.26%) M. Cap (Cr) 948.70 1 Yr Return (%) +2.01% P/E (TTM) 21.87 PB Ratio 5.50

Divis Laboratories Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Divis Laboratories Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 1650.00 Mar 2024 1266.00 Mar 2023 2447.95 Mar 2022 1910.16 Mar 2021 1947.05

PARTICULARS Investing Activities Mar 2025 -803.00 Mar 2024 -268.00 Mar 2023 -2706.75 Mar 2022 -2195.40 Mar 2021 75.34

PARTICULARS Financing Activities Mar 2025 -797.00 Mar 2024 -798.00 Mar 2023 -796.59 Mar 2022 -531.50 Mar 2021 -33.97

PARTICULARS Net Cash Flow Mar 2025 50.00 Mar 2024 200.00 Mar 2023 -1055.39 Mar 2022 -816.74 Mar 2021 1988.42

Divis Laboratories Ltd Shareholding Pattern

This shows the ownership breakdown of Divis Laboratories Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 51.89%

Public 8.96%

Other Institutions 5.78%

FII 19.39%

Mutual Funds 13.99%

About Divis Laboratories Ltd

Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals. The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries. It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. It is among the largest pharmaceutical companies in India with a portfolio of approx. 160 products across diverse therapeutic areas. Presently, it has 6 manufacturing facilities and market presence across several countries. The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale process and structural confirmation.Divi's Laboratories Limited was established in year 1990 as Divis Research Center Limited (DRC) with Research & Development as their prime fundamental. In 1994, they changed their name to Divis Laboratories Limited to reflect their growing area of operations.During the year 1991-93, the company developed several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. In the year 1995, the company started operations in their manufacturing facility (Unit I) at Choutuppal near Hyderabad. In the year 1997, the company was certified as ISO-9002 compliant by SGS-Yarsley of U.K. In the year 1999, European Directorate gave a 'Certificate of Suitability' (CoS) for Naproxen produced by the company. In the year 2001, the company received OHSAS-18001 Certification from BVQI of London for their Occupational Health and Safety Management Systems.In the year 2002, the company commenced setting up of their second manufacturing facility (Unit II) at Chippada near Visakhapatnam. In the year 2003, they opened a new research center christened 'DRC-Vizag' for fundamental research in selected niche business core segments. The company went for initial public offering (IPO) and their shares were listed on Bombay Stock Exchange and National Stock Exchange.In the year 2004, the company invested an amount of Rs 3035.21 lakh towards capital expenditure at their manufacturing facilities at Choutuppal (Unit-I) and Chippada (Unit-II) for additional machinery installed at both Unit-I and Unit-II. In the year 2006, the company received letter of approval from Ministry of Commerce, Government of India, for setting up a sector-specific special economic zone (SEZ) for pharmaceutical ingredients at Chippada, Bheemunipatnam in Visakhapatnam with investment of Rs 200 crore. The company's second manufacturing site at Chippada, was converted into Export Oriented Unit (EOU) and started operations as EOU from June 1, 2006.During the year 2006-07, the company developed an SEZ titled 'Divi's Pharma SEZ' on a 250-acre site at Chippada, Visakhapatnam. During the year 2007-08, the company set up new production as well as utility facilities in SEZ and EOU Units, and enhanced existing capacities at Unit-1. They commissioned Nutraceuticals Manufacturing facility at Divi's Pharma SEZ and commenced commercial operations effective June 1, 2008.During the year 2008-09, the company added 9 products to their product portfolio of which 4 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2009-10, they added 7 products to their product portfolio of which 2 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates.During the year 2010-11, the company added 21 products to their product portfolio of which 8 are generic APIs and intermediates and 13 are custom synthesis APIs and intermediates. The company set up a new facility called 'DSN SEZ Unit' at Chippada in Visakhapatnam at an estimated cost of Rs 200 crore for creating additional capacities for the new opportunities in generic as well as custom synthesis segment. The DSN SEZ Unit commenced commercial operations from June 1, 2011.During the year 2012-13, the company added 9 products to its product portfolio of which 3 are generic APIs and intermediates and 6 are custom synthesis APIs and intermediates.In 2014, the Korean Food and Drug Administration (KFDA) carried out inspection of the company's Visakhapatnam Unit-2 for the third time. During the year, fourth US FDA inspection was carried out at the company's Visakhapatnam Unit-2. Also during the year, fifth US FDA inspection was carried out for Unit-1. During the year, COFEPRIS (Mexico) inspected the company's Visakhapatnam Unit-2 for the first time. COFEPRIS (Mexico) also inspected the company's Choutuppal Unit-1 in Telangana for the first time in the year 2014.On 19 February 2016, Divi's Laboratories announced that it has had a successful inspection by the US-FDA for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February 2016 with no observations.The Board of Directors of Divi's Laboratories at its meeting held on 12 August 2016 approved and ratified one-time ex-gratia of an aggregate amount of Rs 79 crore to the employees and whole-time directors of the company on the occasion of completion of 25 years of formation of the company. On 8 April 2017, Divi's Laboratories announced that the US-FDA has exempted some more products manufactured at the company's Unit-II at Visakhapatnam from import alert issued under clauses 66-40 and 99-32 of the FDA regulations. On 22 April 2017, Divi's Laboratories announced that the US-FDA has issued a warning letter for the company's Unit-II at Visakhapatnam. On 4 August 2017, Divi's Laboratories announced that the inspection of the Unit-2 Visakhapatnam was completed successfully by HPRA (Ireland) and JAZMP (Slovenia). The inspection was focused on follow up on the effectiveness of the CAPA implemented from the last JAZMP inspection and general GMP inspection of the site. On 15 November 2017, Divi's Laboratories announced that the US-FDA has lifted/removed import alert 66-40 imposed on the company's Unit-II at Visakhapatnam.On 18 November 2017, Divi's Laboratories announced that the company has received an Establishment Inspection Report (EIR) from US-FDA for Unit-II at Visakhapatnam, as closure of audit by FDA. On 16 May 2018, Divi's Laboratories announced that its Unit-I at Choutuppal, Telangana has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations.As on 31 March 2018, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products.During the year 2017-18, the company is making capacity additions at the existing manufacturing facilities and in this process we are building 2 additional production blocks at Unit-1 at Choutuppal. Capital WIP as at the year-end amounted to Rs 11976 lakhs. Capital expenditure incurred at the existing Units is to enhance capacities as well as upgrading utilities and infrastructure for compliances. As the company has significant accumulation of cash reserves, all capex has been funded with internal accruals. In order to cater to the increasing opportunities in generic and big pharma business, the Company during the FY2019, is taking up following two brownfield projects with an aggregate investment of Rs 1200 crore.a. An SEZ Unit at our Unit-II at Visakhapatnam, named as DCV SEZ Unit, with an investment of Rs 600 crore. (revised from the estimate of Rs 400 crore announced at the last General Meeting),b. Another SEZ Project with an investment of Rs 600 crore in the available land at our Unit-I in Bhuvangiri-Yadadri (erstwhile Nalgonda) District, Telangana State.The Company has commenced commercial operations from a part of the DC-SEZ Unit in February, 2020, and from a part of the DCV-SEZ Unit in March 2020. The Company has also taken up debottlenecking programs at Unit-I as well as Unit-II by investing an aggregate amount of Rs 300 crore -which would also create additional capacities for existing products. In addition, the company also taken up augmentation of waste treatment infrastructure at Unit-II at an estimated cost of Rs 150 crore. A part of the backward integration, debottlenecking and utility expansion projects have come into utilization this year. The rest of these projects will be completed and come into utilization by end of second half of financial year 2020-21. The balance works of the brownfield projects of DC-SEZ and DCVSEZ are also expected to be completed by second half of financial year 2020-21. As on 31 March 2020, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products.Eventhough there was a nationwide lockdown restrictions due to COVID-19 pandemic since March 24, 2020, the Government has exempted manufacturing units of essential goods including drugs and pharmaceuticals, medical devices, their raw materials and intermediates from the lockdown restrictions, amongst others. The Company has been operating in compliance with the various advisories/ guidelines passed by the Government of India, State Governments and statutory institutions.The new brownfield DC and DCV SEZ Units and the debottlenecking / backward integration programs taken up by the company during the last year, have become fully operational during the FY2021. Also Modernization and upgradation of waste water treatment plants at the manufacturing sites has been implemented. During the year 2020-21, the company also taken up another capex program with an estimated investment of Rs 400 crore for fast-tracking a customs synthesis project.In April, 2023, Company implemented its project of setting up a manufacturing plant (Unit-III) at Kakinada District of Andhra Pradesh.

Chairman & Managing Director

Murali K Divi

Registered office 1-72-23(P)/DIVIS/303 Divi Towe, Cyber Hills Gachibowli, Hyderabad, Telangana, 500032

FAX :91-40-23786300/23786352/400

Background

Incorporation Year 1990

Face Value ₹2.00

Market Lot 1

Divis Laboratories Ltd Latest News

VIEW MORE NEWS

FAQs on Divis Laboratories Ltd